Author Topic: (Lancet) MS progression: Time for a new mechanism-driven framework  (Read 41 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9419
  • MS diagnosed 1980
  • Location: Pacific Northwest
I was able to get access to this article but am not sure that the link will work here. I'm going to give it a try. If anyone has a problem with the link, please let me know, and I will try another method.


This article is long and fairly technical but the authors include some of the names most often seen in MS research, and what they are proposing here is abandoning the classification of MS into relapsing-remitting, secondary progressive and primary progressive forms.  However, they acknowledge that this classification might not be abandoned very soon.


From Lancet Neurology (November 18, 2022), an article on behalf of the International Advisory Committee on Clinical Trials in MS--"Multiple sclerosis progression: time for a new mechanism-driven framework":


https://www.sciencedirect.com/science/article/pii/S1474442222002897
« Last Edit: November 29, 2022, 10:00:32 pm by agate »
MS Speaks--online for 16 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.

Offline agate

  • Administrator
  • *****
  • Posts: 9419
  • MS diagnosed 1980
  • Location: Pacific Northwest
This article is getting attention.  This is from "MS Connections," the newsletter of the MS International Federation (December 15, 2022)--"Pioneering proposal for a new framework to describe types of MS":


https://www.msif.org/news/2022/12/14/pioneering-proposal-for-a-new-framework-to-describe-types-of-ms/
MS Speaks--online for 16 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.

Offline agate

  • Administrator
  • *****
  • Posts: 9419
  • MS diagnosed 1980
  • Location: Pacific Northwest
Press release from ECTRIMS (November 19, 2022)--"International Advisory Committee on Clinical Trials in MS Proposes New 'Mechanism-Driven' Framework to Describe Types of MS":


https://bit.ly/3YJl6VO
MS Speaks--online for 16 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.

Offline agate

  • Administrator
  • *****
  • Posts: 9419
  • MS diagnosed 1980
  • Location: Pacific Northwest
MS Speaks--online for 16 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.

 

Related Topics

  Subject / Started by Replies Last post
0 Replies
77 Views
Last post February 14, 2018, 11:45:36 am
by agate
0 Replies
53 Views
Last post February 04, 2020, 09:06:47 pm
by agate
0 Replies
23 Views
Last post June 20, 2021, 07:30:09 am
by agate
0 Replies
20 Views
Last post November 06, 2021, 09:09:17 pm
by agate
0 Replies
9 Views
Last post May 06, 2022, 10:40:34 am
by agate